Radiomics App v1.0
Microsoft Corp. • Radiology • 12/27/2017
Device Purpose
Microsoft Radiomics App v1.0 is a software-only medical device that employs computerized medical image analysis and machine learning algorithms to assist radiation oncology professionals in generating and refining 3D contours of tumors and healthy organs from CT and MR scans. The system aims to improve the efficiency and accuracy of preparing data for radiation treatment planning through tools for assisted and automated segmentation, image fusion, and 3D visualization.
Summary
Microsoft Radiomics App v1.0 is a software-only medical device designed for use by trained radiation oncologists, dosimetrists, and physicists. Its primary purpose is to assist these professionals in deriving optimal organ and tumor contours from Computed Tomography (CT) and Magnetic Resonance (MR) images, which serve as critical inputs for radiation treatment planning. The application supports loading, saving, and displaying medical images and contours; creating, transforming, and modifying contours for radiotherapy planning, adaptive therapy, and patient follow-up archiving; localizing and defining solid tumors and healthy anatomical structures; fusion display of compatible images; and three-dimensional rendering of medical images and segmented contours. It is specified that images reviewed using the Radiomics App should not be used for primary image interpretations, and the software is not intended for use with digital mammography. The Radiomics App v1.0 is founded on research in computerized medical image analysis, computer vision, and machine learning, employing algorithms for the assisted delineation of anatomical structures in 3D radiological scans. It provides several segmentation tools: an 'Assisted Contouring' module for manual, user-guided segmentation; a 'Machine-learning based contouring' module that uses ML algorithms to provide an initial automatic segmentation which users can accept or refine; and a 'Contour refinement' module for editing segmentations. These segmentations are exported for use in radiotherapy treatment planning systems. Software verification and validation testing, including assessments of measurements, volumetric rendering, multi-planar reconstruction, assisted contouring, and automatic contouring, were conducted to ensure the software performs according to its specifications and meets user needs and intended uses.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of the machine-learning based contouring module vary with different anatomical regions or tumor morphologies in CT versus MR imaging?; What specific machine learning algorithms are implemented, and what was the diversity and size of the datasets used for their training and validation?; Are there published data or internal validation metrics detailing the typical time savings or contour accuracy improvements when using the Radiomics App compared to fully manual contouring?; How does the software handle image artifacts or low-quality scans, and what is the impact on the reliability of both assisted and automated segmentation tools?; What are the specific output formats for the segmented contours, and how seamless is the integration with a range of commercially available radiotherapy treatment planning systems?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly